Ignite Creation Date:
2025-12-25 @ 4:47 AM
Ignite Modification Date:
2025-12-26 @ 3:49 AM
Study NCT ID:
NCT00402818
Status:
TERMINATED
Last Update Posted:
2014-08-29
First Post:
2006-11-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-05
Start Date Type:
None
Primary Completion Date:
2009-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-07
Completion Date Type:
ACTUAL
First Submit Date:
2006-11-20
First Submit QC Date:
None
Study First Post Date:
2006-11-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-08-28
Last Update Post Date:
2014-08-29
Last Update Post Date Type:
ESTIMATED